TABLE 2 MANAGEMENT RECOMMENDATIONS FOR MACULAR HOLE

Stage	Management	Follow-up
1-A and 1-B	Observation ³⁴	Follow-up at 2–4 month intervals in the absence of new symptoms
		 Recommend prompt return if new symptoms develop
		 Encourage monocular visual acuity testing with Amsler grid
2	Vitreoretinal surgery ³⁹ *	Follow-up at 1–2 days postoperatively, then 1–2 weeks
		 Frequency and timing of subsequent visits varies depending on the outcome of surgery and the patient's clinical course
		 If no surgery, follow up every 2–4 months
2	Vitreopharmacolysis†	Follow-up at 1 week and 4 weeks, or with new symptoms (i.e., retinal detachment symptoms)
3 or 4	Vitreoretinal surgery ^{39,43}	Follow-up at 1–2 days postoperatively, then 1–2 weeks
		 Frequency and timing of subsequent visits varies depending on the outcome of surgery and the patient's clinical course

 $[\]ensuremath{^{\star}}$ Although surgery is usually performed, observation may also be appropriate in selected cases.

[†] Although ocriplasmin has been approved by the U.S. Food and Drug Administration for vitreomacular adhesion, its use for treatment of idiopathic macular hole without vitreomacular traction or adhesion would currently be considered off-label use.